← Back to Search

Stage II/III Colorectal Cancer, without Recurrence (Training) for Colorectal Cancer (CENSURE Trial)

N/A
Recruiting
Led By Ajay Goel, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 120 months
Awards & highlights

CENSURE Trial Summary

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Eligible Conditions
  • Colorectal Cancer

CENSURE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 120 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 120 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence-Free Survival
Secondary outcome measures
Overall Survival

CENSURE Trial Design

4Treatment groups
Experimental Treatment
Group I: Stage II/III Colorectal Cancer, without Recurrence (Validation)Experimental Treatment1 Intervention
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
Group II: Stage II/III Colorectal Cancer, without Recurrence (Training)Experimental Treatment1 Intervention
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
Group III: Stage II/III Colorectal Cancer, with Recurrence (Validation)Experimental Treatment1 Intervention
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
Group IV: Stage II/III Colorectal Cancer, with Recurrence (Training)Experimental Treatment1 Intervention
Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,060 Total Patients Enrolled
Ajay Goel, PhDPrincipal InvestigatorCity of Hope Medical Center
6 Previous Clinical Trials
3,977 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
CA: A Cancer Journal for CliniciansJournal
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians. Wiley. doi:10.3322/caac.21660.
clinicaltrials.govStudy
Stage II/III Colorectal Cancer Recurrence
2023. "Stage II/III Colorectal Cancer Recurrence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06314958.
All > Anaheim > Paid Studies Ventura
~167 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top